Heparin-protein interactions.
暂无分享,去创建一个
[1] A. Luster,et al. Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.
[2] J. Putten,et al. Vitronectin binds to the gonococcal adhesin OpaA through a glycosaminoglycan molecular bridge. , 1998, The Biochemical journal.
[3] J. Holbrook,et al. The interaction of platelet factor 4 with heparins of different chain length. , 1984, Biochimica et biophysica acta.
[4] N. Heegaard,et al. A heparin‐binding peptide from human serum amyloid P component characterized by affinity capillary electrophoresis , 1998, Electrophoresis.
[5] B. Seaton,et al. Interaction of heparin with annexin V , 1999, FEBS letters.
[6] A. R. Todd,et al. Observations on the structure of the barium salt of heparin. , 1940, The Biochemical journal.
[7] R. Rosenberg,et al. The purification and mechanism of action of human antithrombin-heparin cofactor. , 1973, The Journal of biological chemistry.
[8] T. Springer,et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) , 1996, The Journal of experimental medicine.
[9] A. Lander,et al. Differential binding of chemokines to glycosaminoglycan subpopulations , 1994, Current Biology.
[10] J. Feeney,et al. Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. , 1994, Biochemistry.
[11] M. Auer,et al. Transcytosis and Surface Presentation of IL-8 by Venular Endothelial Cells , 1997, Cell.
[12] K. Mayo,et al. Heparin Dodecasaccharide Binding to Platelet Factor-4 and Growth-related Protein-α , 1999, The Journal of Biological Chemistry.
[13] R. Linhardt,et al. Conformational study of synthetic delta 4-uronate monosaccharides and glycosaminoglycan-derived disaccharides. , 1998, Carbohydrate research.
[14] C. V. van Noorden,et al. The complex effects of heparins on cancer progression and metastasis in experimental studies. , 2001, Pharmacological reviews.
[15] R. Langer,et al. Heparinase III from Flavobacterium heparinum: cloning and recombinant expression in Escherichia coli. , 1996, Biochemical and biophysical research communications.
[16] Cornelis Altona,et al. Force field parameters for sulfates and sulfamates based on ab initio calculations: Extensions of AMBER and CHARMm fields , 1995, J. Comput. Chem..
[17] R. Hubbard,et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. , 1999, Biochemistry.
[18] H. Kitagawa,et al. Characterization of recombinant human glucuronyltransferase I involved in the biosynthesis of the glycosaminoglycan‐protein linkage region of proteoglycans , 1999, FEBS letters.
[19] R. Linhardt,et al. Interaction of Secretory Leukocyte Protease Inhibitor with Heparin Inhibits Proteases Involved in Asthma* , 1998, The Journal of Biological Chemistry.
[20] M. Petitou,et al. Interaction of heparin and antithrombin III. The role of O-sulfate groups. , 1988, European journal of biochemistry.
[21] R. Sasisekharan,et al. Heparinase I from Flavobacterium heparinum , 1998, The Journal of Biological Chemistry.
[22] Rebecca C. Wade,et al. Docking of Glycosaminoglycans to Heparin-Binding Proteins: Validation for aFGF, bFGF, and Antithrombin and Application to IL-8 , 1999 .
[23] C L Cooney,et al. Heparinase inhibits neovascularization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Cardin,et al. Molecular Modeling of Protein‐Glycosaminoglycan Interactions , 1989, Arteriosclerosis.
[25] B. Edwards,et al. A model of the platelet factor 4 complex with heparin , 1992, Proteins.
[26] R. Linhardt,et al. Regio and stereoselective conversion of Δ4-uronic acids to l-Ido- and d-glucopyranosiduronic acids , 1997 .
[27] A. Zlotnik,et al. The biology of chemokines and their receptors. , 2000, Annual review of immunology.
[28] M. Nybo,et al. Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: enhanced binding at slightly acid pH. , 1997, Biochimica et biophysica acta.
[29] Steven M. Wolinsky,et al. The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.
[30] Pablo Engel,et al. The selecting: vascular adhesion molecules , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] J. Weiler,et al. Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. , 1996, The international journal of biochemistry & cell biology.
[32] Maurice Petitou,et al. Die ersten synthetischen Kohlenhydrate mit den vollständigen antikoagulierenden Eigenschaften von Heparin , 1998 .
[33] A. Levinson,et al. The Transforming Growth Factor‐Betas: A New Family of Immunoregulatory Molecules , 1990, Annals of the New York Academy of Sciences.
[34] R. Linhardt,et al. Purification and characterization of a novel heparinase from Bacteroides stercoris HJ-15. , 2000, Journal of biochemistry.
[35] R. Linhardt,et al. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. , 2000, Thrombosis research.
[36] U. Lindahl,et al. Biosynthesis of heparin. The D-glucuronosyl- and N-acetyl-D-glucosaminyltransferase reactions and their relation to polymer modification. , 1992, The Biochemical journal.
[37] K. Biemann,et al. Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Linhardt,et al. Isolation and characterization of heparan sulfate from crude porcine intestinal mucosal peptidoglycan heparin. , 1995, Carbohydrate research.
[39] E. Appella,et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[40] B. Herold,et al. Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. , 1992, Advances in experimental medicine and biology.
[41] A. M. Saunders,et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.
[42] H. Rauvala. An 18‐kd heparin‐binding protein of developing brain that is distinct from fibroblast growth factors. , 1989, The EMBO journal.
[43] B. Rupp,et al. Interaction of the N-terminal domain of apolipoprotein E4 with heparin. , 2001, Biochemistry.
[44] H. Hamazaki. Ca2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. , 1987, The Journal of biological chemistry.
[45] C. W. von der Lieth,et al. Efficient modelling protocols for oligosaccharides: from vacuum to solvent , 1997, Glycoconjugate Journal.
[46] S. Moss,et al. Annexins and membrane dynamics. , 1997, Biochimica et biophysica acta.
[47] Luigi Buonaguro,et al. HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.
[48] Anne Imberty,et al. Characterization of the Stromal Cell-derived Factor-1α-Heparin Complex* , 2001, The Journal of Biological Chemistry.
[49] J. Weiler,et al. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. , 1995, Archives of biochemistry and biophysics.
[50] D. Rees,et al. Diversity does make a difference: fibroblast growth factor-heparin interactions. , 1998, Current opinion in structural biology.
[51] M. Charng,et al. FKBP-12 Recognition Is Dispensable For Signal Generation by Type I Transforming Growth Factor-β Receptors* , 1996, The Journal of Biological Chemistry.
[52] J. Dawes. Measurement of the affinities of heparins, naturally occurring glycosaminoglycans, and other sulfated polymers for antithrombin III and thrombin. , 1988, Analytical biochemistry.
[53] B. Faller,et al. Heparin-induced conformational change and activation of mucus proteinase inhibitor. , 1992, Biochemistry.
[54] J. Esko,et al. An Animal Cell Mutant Defective in Heparan Sulfate Hexuronic Acid 2-O-Sulfation* , 1996, The Journal of Biological Chemistry.
[55] J. Turnbull,et al. Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. , 1994, The Journal of biological chemistry.
[56] T. Shimomura,et al. Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes. , 1993, Experimental cell research.
[57] J. Sparrow,et al. Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. , 1986, Biochemical and biophysical research communications.
[58] T. Krusat,et al. Heparin-dependent attachment ofrespiratory syncytial virus (RSV) to host cells , 1997, Archives of Virology.
[59] J. Holbrook,et al. Low-resolution structure of the complex of human blood platelet factor 4 with heparin determined by small-angle neutron scattering. , 1986, Biochimica et biophysica acta.
[60] A. Varki,et al. Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. , 1993, Science.
[61] K. Yoshida,et al. Human Homolog of Caenorhabditis elegans sqv-3 Gene Is Galactosyltransferase I Involved in the Biosynthesis of the Glycosaminoglycan-Protein Linkage Region of Proteoglycans* , 1999, The Journal of Biological Chemistry.
[62] R. Linhardt,et al. Nature of the interaction of heparin with acidic fibroblast growth factor. , 1993, Biochemistry.
[63] L. Naldini,et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth , 1992, The Journal of cell biology.
[64] H. Messmore,et al. State-of-the-Art Review : Heparin-induced Thrombocytopenia and Thrombosis Syndrome , 1998 .
[65] U. Desai,et al. Role of Arginine 129 in Heparin Binding and Activation of Antithrombin* , 2000, The Journal of Biological Chemistry.
[66] B. Herold,et al. Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B. , 1994, The Journal of general virology.
[67] A. Lander,et al. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[68] R. Linhardt,et al. Thermodynamic analysis of the heparin interaction with a basic cyclic peptide using isothermal titration calorimetry. , 1998, Biochemistry.
[69] T. Muramatsu,et al. Expression of a carbohydrate signal, sialyl dimeric Le(x) antigen, is associated with metastatic potential of transitional cell carcinoma of the human urinary bladder. , 1991, Biochemical and biophysical research communications.
[70] C. Parish,et al. A rapid quantitative assay for the detection of mammalian heparanase activity. , 1997, The Biochemical journal.
[71] D. Ornitz,et al. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.
[72] P. Fraser,et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease , 1995, Nature Medicine.
[73] Z. Shriver,et al. Heparinase II from Flavobacterium heparinum , 1998, The Journal of Biological Chemistry.
[74] D. Hoppensteadt,et al. An update on heparins at the beginning of the new millennium. , 2000, Seminars in thrombosis and hemostasis.
[75] R. Samulski,et al. Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.
[76] Simi Ali,et al. Examination of the Function of RANTES, MIP-1α, and MIP-1β following Interaction with Heparin-like Glycosaminoglycans* , 2000, The Journal of Biological Chemistry.
[77] U. Lindahl,et al. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[78] W. Sicinska,et al. A detailed 1H and 13C NMR study of a repeating disaccharide of hyaluronan: the effects of temperature and counterion type. , 1993, Carbohydrate research.
[79] A. Varki,et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. , 1998, The Journal of clinical investigation.
[80] H. Rubin. Serine protease inhibitors (SERPINS): Where mechanism meets medicine , 1996, Nature Medicine.
[81] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[82] X. Wu,et al. Requirement for Anticoagulant Heparan Sulfate in the Fibroblast Growth Factor Receptor Complex* , 1999, The Journal of Biological Chemistry.
[83] S. Stringer,et al. Specific Binding of the Chemokine Platelet Factor 4 to Heparan Sulfate* , 1997, The Journal of Biological Chemistry.
[84] M Sobel,et al. Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes. , 1996, Archives of biochemistry and biophysics.
[85] H. Nader,et al. Conformation of the Unsaturated Uronic Acid Residues of Glycosamtnoglycan Disaccharides , 1993 .
[86] C. McCormick,et al. The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[87] I. Danishefsky,et al. Preparation of highly stable antithrombin-sepharose and utilization for the fractionation of heparin. , 1982, Thrombosis research.
[88] A. Malmström,et al. Biosynthesis of L-iduronic acid in heparin: epimerization of D-glucuronic acid on the polymer level. , 1972, Biochemical and biophysical research communications.
[89] A. Aruffo,et al. Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[90] R. Carrell,et al. Heparin binding site, conformational change, and activation of antithrombin. , 1992, Biochemistry.
[91] D. Hoover,et al. The Crystal Structure of the Chemokine Domain of Fractalkine Shows a Novel Quaternary Arrangement* , 2000, The Journal of Biological Chemistry.
[92] M. Forster,et al. N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.
[93] H. Kitagawa,et al. Molecular Cloning and Expression of Glucuronyltransferase I Involved in the Biosynthesis of the Glycosaminoglycan-Protein Linkage Region of Proteoglycans* , 1998, The Journal of Biological Chemistry.
[94] I. Danishefsky,et al. Evidence for a heparin-induced conformational change on antithrombin III. , 1977, Biochemical and biophysical research communications.
[95] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[96] E. Henningsson,et al. Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III--thrombin complex. , 1977, Journal of immunological methods.
[97] J. Weiler,et al. Two-dimensional affinity resolution electrophoresis demonstrates that three distinct heparin populations interact with antithrombin III. , 1995, Biochemistry.
[98] K. Biemann,et al. Mass spectrometric evidence for the enzymatic mechanism of the depolymerization of heparin-like glycosaminoglycans by heparinase II. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[99] F. Robey,et al. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. , 1992, The Journal of biological chemistry.
[100] R. Kisilevsky,et al. Sulfated glycosaminoglycans: a common constituent of all amyloids? , 1987, Laboratory investigation; a journal of technical methods and pathology.
[101] Joseph Sodroski,et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.
[102] U. R. Desai,et al. Specificity studies on the heparin lyases from Flavobacterium heparinum. , 1993, Biochemistry.
[103] J. Rand,et al. Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. , 1997, The New England journal of medicine.
[104] P. Fisher,et al. Expression of Human Papilloma Virus E7 Protein Causes Apoptosis and Inhibits DNA Synthesis in Primary Hepatocytes via Increased Expression of p21Cip-1/WAF1/MDA6 * , 2000, The Journal of Biological Chemistry.
[105] T. McCutchan,et al. Heparin can regulate the binding of Plasmodium falciparum circumsporozoite protein. , 2000, Molecular and biochemical parasitology.
[106] M. Konishi,et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. , 2000, Biochimica et biophysica acta.
[107] P. Wingfield,et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation , 1993, Journal of virology.
[108] V. Nussenzweig,et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of plasmodium falciparum sporozoites , 1992, Cell.
[109] J. Fareed,et al. STRUCTURAL STUDIES ON A BIOLOGICALLY ACTIVE HEXASACCHARIDE OBTAINED FROM HEPARIN , 1981, Annals of the New York Academy of Sciences.
[110] Bernhard Moser,et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.
[111] D. Waisman,et al. Characterization of the Heparin Binding Properties of Annexin II Tetramer* , 1997, The Journal of Biological Chemistry.
[112] R. Langer,et al. Cloning and expression of heparinase I gene from Flavobacterium heparinum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[113] M. Delepierre,et al. Stromal Cell-derived Factor-1α Associates with Heparan Sulfates through the First β-Strand of the Chemokine* , 1999, The Journal of Biological Chemistry.
[114] J. Herbert,et al. First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin. , 1998, Angewandte Chemie.
[115] S. V. van Duinen,et al. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. , 1988, Laboratory investigation; a journal of technical methods and pathology.
[116] E. Jorpes,et al. Der Aminozucker des Heparins. , 1936 .
[117] J. Spring,et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. , 1992, Annual review of cell biology.
[118] H. Su,et al. Isolation and expression in Escherichia coli of hepB and hepC, genes coding for the glycosaminoglycan-degrading enzymes heparinase II and heparinase III, respectively, from Flavobacterium heparinum , 1996, Applied and environmental microbiology.
[119] D. Spillmann,et al. Characterization of Heparin and Heparan Sulfate Domains Binding to the Long Splice Variant of Platelet-derived Growth Factor A Chain* , 1997, The Journal of Biological Chemistry.
[120] J. Abraham,et al. Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. , 1994, The Journal of biological chemistry.
[121] A. Drake,et al. The effect of variation of substitution on the solution conformation of heparin: a spectroscopic and molecular modelling study. , 1994, Carbohydrate research.
[122] B. Seaton,et al. Annexin V--heparin oligosaccharide complex suggests heparan sulfate--mediated assembly on cell surfaces. , 2001, Structure.
[123] David R. Nadeau,et al. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[124] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[125] G. Waksman,et al. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. , 1995, Science.
[126] B. Svennerholm,et al. Herpes Simplex Virus Types 1 and 2 Differ in Their Interaction with Heparan Sulfate , 2000, Journal of Virology.
[127] R. Langer,et al. Heparinase I from Flavobacterium heparinum. Identification of a critical histidine residue essential for catalysis as probed by chemical modification and site-directed mutagenesis. , 1996, Biochemistry.
[128] J. Walenga,et al. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. , 1998, The Medical clinics of North America.
[129] R. Yolken,et al. Human milk glycosaminoglycans inhibit HIV glycoprotein gp120 binding to its host cell CD4 receptor. , 1995, The Journal of nutrition.
[130] U. Desai,et al. Mechanism of Heparin Activation of Antithrombin , 1998, The Journal of Biological Chemistry.
[131] Q. Sattentau,et al. The CD4 antigen: Physiological ligand and HIV receptor , 1988, Cell.
[132] P. Sanderson,et al. Conformational equilibria of alpha-L-iduronate residues in disaccharides derived from heparin. , 1987, The Biochemical journal.
[133] B. Casu,et al. Structure and biological activity of heparin. , 1985, Advances in carbohydrate chemistry and biochemistry.
[134] R. Linhardt,et al. Preparation and structure of heparin lyase-derived heparan sulfate oligosaccharides. , 1997, Glycobiology.
[135] K. Yoshida,et al. Importance of 2-O-sulfate groups of uronate residues in heparin for activation of FGF-1 and FGF-2. , 1995, Journal of biochemistry.
[136] M. Kaksonen,et al. Heparin-binding Growth-associated Molecule Contains Two Heparin-binding β-Sheet Domains That Are Homologous to the Thrombospondin Type I Repeat* , 2000, The Journal of Biological Chemistry.
[137] D. Feingold,et al. A vintage year for Jorpes, Crafoord, and heparin , 1985 .
[138] T. Peters,et al. Conformational analysis of synthetic heparin-like oligosaccharides containing α-L-idopyranosyluronic acid† , 1987 .
[139] M. Baggiolini,et al. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[140] J. Schlessinger,et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. , 2000, Molecular cell.
[141] D C Rees,et al. Heparin Structure and Interactions with Basic Fibroblast Growth Factor , 1996, Science.
[142] B. Moss,et al. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[143] J. Weiler,et al. Heparin and modified heparin inhibit complement activation in vivo. , 1992, Journal of immunology.
[144] J. Thompson,et al. Heparin-dependent fibroblast growth factor activities: effects of defined heparin oligosaccharides. , 1997, European Journal of Cell Biology.
[145] Z. Shriver,et al. Histidine 295 and histidine 510 are crucial for the enzymatic degradation of heparan sulfate by heparinase III. , 2000, Biochemistry.
[146] J. Goudsmit,et al. Neutralization of HIV‐1: a paradox of humoral proportions , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[147] J. Luban,et al. Specific incorporation of cyclophilin A into HIV-1 virions , 1994, Nature.
[148] R. Linhardt,et al. Interaction of soluble and surface‐bound heparin binding growth‐associated molecule with heparin , 1999, FEBS letters.
[149] N. Cooper,et al. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. , 1993, Virology.
[150] B. Herold,et al. Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry , 1996, Journal of virology.
[151] J. Pelt,et al. Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes , 1997, Journal of viral hepatitis.
[152] J. Xu,et al. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. , 1993, Science.
[153] O. Ratnoff,et al. SOME PROPERTIES OF AN ESTERASE DERIVED FROM PREPARATIONS OF THE FIRST COMPONENT OF COMPLEMENT , 1957, The Journal of experimental medicine.
[154] K. Rice,et al. Interterminal distance and flexibility of a triantennary glycopeptide as measured by resonance energy transfer. , 1991, Biochemistry.
[155] David F. Burke,et al. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin , 2000, Nature.
[156] J. Weiler,et al. Heparin binding and augmentation of C1 inhibitor activity. , 1999, Archives of biochemistry and biophysics.
[157] R. Langer,et al. An enzymatic system for removing heparin in extracorporeal therapy. , 1982, Science.
[158] Q. Sattentau,et al. Human Immunodeficiency Virus Type 1 Attachment to HeLa CD4 Cells Is CD4 Independent and gp120 Dependent and Requires Cell Surface Heparans , 1998, Journal of Virology.
[159] V. Nussenzweig,et al. Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes , 1996, The Journal of experimental medicine.
[160] J. V. van Putten,et al. Entry of OpaA+ gonococci into HEp‐2 cells requires concerted action of glycosaminoglycans, fibronectin and integrin receptors , 1998, Molecular microbiology.
[161] M. D. Freedman,et al. Pharmacodynamics, Clinical Indications, and Adverse Effects of Heparin , 1992, Journal of clinical pharmacology.
[162] I. Vlodavsky,et al. Substrate Specificity of Heparanases from Human Hepatoma and Platelets* , 1998, The Journal of Biological Chemistry.
[163] K. Nagaki,et al. Inactivator of the First Component of Human Complement (CĪINA) , 1974 .
[164] R. Mahley,et al. Human apolipoprotein E: the Alzheimer's disease connection , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[165] T. Yeatman,et al. Expression of annexins on the surfaces of non-metastatic and metastatic human and rodent tumor cells , 2004, Clinical & Experimental Metastasis.
[166] Jian Liu,et al. Purification of Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase* , 1996, The Journal of Biological Chemistry.
[167] A. Varki,et al. Selectin ligands. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[168] R. Langer,et al. Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum. , 1996, The Biochemical journal.
[169] D. Spillmann,et al. More to "heparin" than anticoagulation. , 1994, Thrombosis research.
[170] H. Rauvala,et al. Neurite Outgrowth in Brain Neurons Induced by Heparin-binding Growth-associated Molecule (HB-GAM) Depends on the Specific Interaction of HB-GAM with Heparan Sulfate at the Cell Surface (*) , 1996, The Journal of Biological Chemistry.
[171] R. Mahley,et al. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. , 1986, The Journal of biological chemistry.
[172] D. Arveiler,et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[173] J. Weiler,et al. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. , 1994, Immunopharmacology.
[174] A. Velázquez‐Campoy,et al. Isothermal titration calorimetry , 1990 .
[175] R. Sasisekharan,et al. A comparative analysis of the primary sequences and characteristics of heparinases I, II, and III from Flavobacterium heparinum. , 1996, Biochemical and biophysical research communications.
[176] T. McCaffrey,et al. Transforming growth factor‐β1 is a heparin‐binding protein: Identification of putative heparin‐binding regions and isolation of heparins with varying affinity for TGF‐β1 , 1992 .
[177] S. Soker,et al. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. , 1992, The Journal of biological chemistry.
[178] K. Holme,et al. Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding. , 1995, Virology.
[179] Å. Danielsson,et al. Denaturation behavior of antithrombin in guanidinium chloride. Irreversibility of unfolding caused by aggregation. , 1985, Biochemistry.
[180] S. Hoffman,et al. Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates , 1992, The Journal of cell biology.
[181] J. Weiler,et al. Interaction of fibroblast growth factor-1 and related peptides with heparan sulfate and its oligosaccharides. , 1997, Archives of biochemistry and biophysics.
[182] T. Lohman,et al. Thermodynamics of ligand-nucleic acid interactions. , 1992, Methods in enzymology.
[183] R. Kalaria,et al. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders , 1991, Neuropathology and applied neurobiology.
[184] R. Belland,et al. Adherence of pilus- Opa+ gonococci to epithelial cells in vitro involves heparan sulfate , 1995, The Journal of experimental medicine.
[185] A. Varki,et al. Endothelial Heparan Sulfate Proteoglycans That Bind to L-Selectin Have Glucosamine Residues with Unsubstituted Amino Groups (*) , 1995, The Journal of Biological Chemistry.
[186] D. Stuart,et al. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate , 1996, Journal of virology.
[187] J. Huntington,et al. Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding. , 1996, Biochemistry.
[188] W. Langdon,et al. c-Cbl Is Transiently Tyrosine-phosphorylated, Ubiquitinated, and Membrane-targeted following CSF-1 Stimulation of Macrophages (*) , 1996, The Journal of Biological Chemistry.
[189] G. Torri,et al. Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. , 1985, Biochemical and biophysical research communications.
[190] T. Lohman,et al. Ion effects on ligand-nucleic acid interactions. , 1976, Journal of molecular biology.
[191] J. Benz,et al. Annexins: from structure to function. , 1997, Biological chemistry.
[192] R. Peters,et al. Low-molecular Weight Heparins in Venous and Arterial Thrombotic Disease , 1999, Thrombosis and Haemostasis.
[193] A. Delacourte,et al. Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide , 1993, Brain Research.
[194] E. Bennett,et al. Cloning and Expression of a Proteoglycan UDP-Galactose:β-Xylose β1,4-Galactosyltransferase I , 1999, The Journal of Biological Chemistry.
[195] Wayne A. Hendrickson,et al. Structure of a heparin-linked biologically active dimer of fibroblast growth factor , 1998, Nature.
[196] H. Halvorson,et al. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. , 1991, The Journal of biological chemistry.
[197] R. Linhardt,et al. Order out of complexity--protein structures that interact with heparin. , 2001, Current opinion in structural biology.
[198] Martin A. Garrett. The LIGO Scientific Collaboration , 2010 .
[199] M. Pantoliano,et al. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. , 1994, Biochemistry.
[200] U. R. Desai,et al. Interaction of heparin with synthetic antithrombin III peptide analogues. , 1994, The Biochemical journal.
[201] J. Turnbull,et al. Patterns of sulphation in heparan sulphate: polymorphism based on a common structural theme. , 1992, The International journal of biochemistry.
[202] L. Callahan,et al. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions , 1991, Journal of virology.
[203] C. Power,et al. Glycosaminoglycans mediate cell surface oligomerization of chemokines. , 1997, Biochemistry.
[204] M. Sobel,et al. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. , 1992, The Journal of biological chemistry.
[205] M. Petitou,et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. , 1983, Biochemical and biophysical research communications.
[206] J. Sodroski,et al. Functional association of cyclophilin A with HIV-1 virions , 1994, Nature.
[207] I. Björk,et al. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. , 1977, Thrombosis research.
[208] J. V. van Putten,et al. Sulfated Polysaccharide-Directed Recruitment of Mammalian Host Proteins: a Novel Strategy in Microbial Pathogenesis , 1999, Infection and Immunity.
[209] J. Hopwood,et al. Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin , 1976, FEBS letters.
[210] G. S. Manning. On the application of polyelectrolyte “limiting laws” to the helix‐coil transition of DNA. I. Excess univalent cations , 1972, Biopolymers.
[211] R. Linhardt,et al. NMR solution conformation of heparin-derived hexasaccharide. , 1996, The Biochemical journal.
[212] U. R. Desai,et al. Substrate specificity of the heparin lyases from Flavobacterium heparinum. , 1993, Archives of biochemistry and biophysics.
[213] J. Esko,et al. Turnover of Heparan Sulfate Depends on 2-O-Sulfation of Uronic Acids* , 1997, The Journal of Biological Chemistry.
[214] J. Platt,et al. Heparanase, a potential regulator of cell-matrix interactions. , 2000, Trends in biochemical sciences.
[215] R. Eisenberg,et al. A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 Entry , 1999, Cell.
[216] M. Nugent,et al. Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. , 2000, Biochemistry.
[217] I. Turko,et al. Lysine-heparin interactions in antithrombin. Properties of K125M and K290M,K294M,K297M variants. , 1994, Biochemistry.
[218] E. Goldsmith,et al. Serpins: the uncut version. , 1994, Structure.
[219] I. Björk,et al. The role of Arg46 and Arg47 of antithrombin in heparin binding. , 1999, Biochemistry.
[220] M. Giacca,et al. Interaction of HIV-1 Tat Protein with Heparin , 1997, The Journal of Biological Chemistry.
[221] W. Hendrickson,et al. CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target. , 1991, Current opinion in biotechnology.
[222] H. Gewurz,et al. Potentiation of C1-esterase inhibitor activity by heparin , 1976 .
[223] Oliver J. C. Rick,et al. Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection , 1996, FEBS letters.
[224] J. Turnbull,et al. Heparan sulphate proteoglycans: molecular organisation of membrane--associated species and an approach to polysaccharide sequence analysis. , 1992, Advances in experimental medicine and biology.
[225] K. Haustein. Pharmacokinetic and Pharmacodynamic Properties of Oral Anticoagulants, Especially Phenprocoumon , 1999, Seminars in thrombosis and hemostasis.
[226] H. Ogawa,et al. Glycosaminoglycan Binding Properties of Annexin IV, V, and VI* , 1998, The Journal of Biological Chemistry.
[227] A. Linker,et al. Structure of the antithrombin-binding site in heparin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[228] R. Linhardt,et al. Enzymatic modification of heparan sulfate on a biochip promotes its interaction with antithrombin III. , 2000, Biochemical and biophysical research communications.
[229] C. Rider. The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection , 1997, Glycoconjugate Journal.
[230] A. Perlin,et al. A proton magnetic resonance spectral study of heparin. : L-Iduronic acid residues in commercial heparins , 1968 .
[231] V. Nussenzweig,et al. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes , 1993, The Journal of experimental medicine.
[232] R. Linhardt,et al. Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding. , 1997, Biochemical and biophysical research communications.
[233] R. Linhardt,et al. Preparation and structural characterization of large heparin-derived oligosaccharides. , 1995, Glycobiology.
[234] J. Esko,et al. Repetitive Ser-Gly Sequences Enhance Heparan Sulfate Assembly in Proteoglycans (*) , 1995, The Journal of Biological Chemistry.
[235] S. Straus,et al. Specificity and affinity of binding of herpes simplex virus type 2 glycoprotein B to glycosaminoglycans , 1997, Journal of virology.
[236] C. Power,et al. Definition, function and pathophysiological significance of chemokine receptors. , 1998, Trends in pharmacological sciences.
[237] T. Irimura,et al. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. , 1983, Science.
[238] T. Lohman,et al. Thermodynamics of charged oligopeptide-heparin interactions. , 1995, Biochemistry.
[239] J. Weiler,et al. Pattern and spacing of basic amino acids in heparin binding sites. , 1997, Archives of biochemistry and biophysics.
[240] J. Abrahams,et al. The anticoagulant activation of antithrombin by heparin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[241] C. Rider,et al. Heparin specifically inhibits binding of V3 loop antibodies to HIV‐1 gp120, an effect potentiated by CD4 binding , 1994, AIDS.
[242] William C. Olson,et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.
[243] D. Spillmann,et al. Structural Requirement of Heparan Sulfate for Interaction with Herpes Simplex Virus Type 1 Virions and Isolated Glycoprotein C* , 1997, The Journal of Biological Chemistry.
[244] K. Murthy,et al. RETRACTED: Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activation and Binds Heparan Sulfate Proteoglycans , 2001, Cell.
[245] H. Engelberg. Orally Ingested Heparin Is Absorbed in, Humans , 1995 .
[246] R. Rosenberg,et al. Correlation between structure and function of heparin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[247] J. Weiler,et al. Glycosaminoglycan‐protein interactions: definition of consensus sites in glycosaminoglycan binding proteins , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[248] P. Gallay,et al. Host cyclophilin A mediates HIV‐1 attachment to target cells via heparans , 1999, The EMBO journal.
[249] U. R. Desai,et al. Structure elucidation of a novel acidic tetrasaccharide and hexasaccharide derived from a chemically modified heparin. , 1993, Carbohydrate research.
[250] N. Copeland,et al. Multiple Isoforms of Heparan Sulfate d-Glucosaminyl 3-O-Sulfotransferase , 1999, The Journal of Biological Chemistry.
[251] H. Kitagawa,et al. Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. , 2000, Current opinion in structural biology.
[252] T. Irimura,et al. Tumor metastasis-associated heparanase (heparan sulfate endoglycosidase) activity in human melanoma cells. , 1986, Cancer letters.
[253] C. Best,et al. Preparation of Heparin and Its Use in the First Clinical Cases , 1959, Circulation.
[254] J. J. Schwartz,et al. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? , 1997, The Journal of clinical investigation.
[255] M. Götte,et al. Functions of cell surface heparan sulfate proteoglycans. , 1999, Annual review of biochemistry.
[256] D. Spillmann,et al. Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.
[257] R. Mahley,et al. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. , 1999, Journal of lipid research.
[258] P. Roepstorff,et al. Ligand-binding sites in human serum amyloid P component. , 1996, European journal of biochemistry.
[259] M. Salmivirta,et al. Heparan sulfate : a piece of information , 2004 .
[260] M. Giacca,et al. Multiple Interactions of HIV-I Tat Protein with Size-defined Heparin Oligosaccharides* , 1999, The Journal of Biological Chemistry.
[261] E. Recondo,et al. The first component of the human complement system recognizes the active fraction of heparin. , 1997, Cellular and molecular biology.
[262] G. Siest,et al. Kinetics of apolipoprotein E isoforms‐binding to the major glycosaminoglycans of the extracellular matrix , 1999, FEBS letters.
[263] M. Levine,et al. Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread , 1999, Thrombosis and Haemostasis.
[264] M. Nakajima,et al. Human Heparanase , 1999, The Journal of Biological Chemistry.
[265] J. Gluckman,et al. Glycan and glycosaminoglycan binding properties of stromal cell-derived factor (SDF)-1alpha. , 2000, Glycobiology.
[266] L. Bernier,et al. Apolipoprotein E and atherosclerosis: insight from animal and human studies. , 1999, Clinica chimica acta; international journal of clinical chemistry.
[267] R. Linhardt,et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. , 1993, Blood.
[268] M. Burdick,et al. CXC chemokines in angiogenesis , 2000, Journal of leukocyte biology.
[269] Benito Casu,et al. Evidence for conformational equilibrium of the sulfated L-iduronate residue in heparin and in synthetic heparin mono- and oligo-saccharides: NMR and force-field studies , 1986 .
[270] J. Esko,et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate , 1997, Nature Medicine.